New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia.
A strongly improved balance sheet, new shareholders and an entrepreneurial management to support the group’s development going forward.
New protein A media boosts productivity in monoclonal and polyclonal antibody capture, lowers costs.
All Novasep Synthesis sites pass FDA inspections in last three years.
Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds. Joint technical showcase presentation at Informex, Charlotte, NC, USA, Feb 7, Booth: 1987
Joint project will offer a cost-effective, environmentally friendly process to produce betaine, an animal feed ingredient in short supply.
Novasep’s role in scaling up this patented process helped Nutritis close a EUR 13.5M financing round and acquire a fructose unit exclusively for fruit processing.
Electrodialysis and manufacturing process companies come together to design the most cost-effective whey demineralization solutions offering guaranteed performance.
Novasep appoints a new Chairman for its Supervisory Board Bernard Dubois, former Aventis Senior VP of Global Industrial Operations brings a wealth of experience to Novasep’s top management team.
July 26, 2010 - Toulouse and Pompey, France: Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce today that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.